Reference number : 236-2018-2019-Q2-00342, amendment number : , agreement type : G, recipient legal name : Latifovic, Lidija, recipient country : CA, recipient province : ON, recipient city : Toronto, recipient postal code : M5G 2C4, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 105000.0, agreement start date : 2018-09-01, agreement end date : 2021-08-31, description english : A genetic analysis of the pharmacokinetic and pharmacodynamic pathways of cetuximab; to assess efficacy and toxicity outcomes in chemotherapy-refractory, metastatic colorectal cancer patients from the Canadian Cancer Trials Group CO.20 and CO.17 trials., description french : A genetic analysis of the pharmacokinetic and pharmacodynamic pathways of cetuximab; to assess efficacy and toxicity outcomes in chemotherapy-refractory, metastatic colorectal cancer patients from the Canadian Cancer Trials Group CO.20 and CO.17 trials., expected results english : nan, expected results french : nan, additional information english : nan, additional information french : nan, owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada